Myovant Financial Statements From 2010 to 2021

MYOV -  USA Stock  

USD 20.28  0.22  1.07%

Myovant Sciences financial statements provide useful quarterly and yearly information to potential Myovant Sciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Myovant Sciences financial statements helps investors assess Myovant Sciences' valuation, profitability, and current liquidity needs.
There are over sixty-six available fundamental ratios for Myovant Sciences, which can be analyzed over time and compared to other ratios. Please make sure you check Myovant Sciences' last-minute fundamental trends against the trends from 2010 to 2021 to make sure the company is sustainable.
Myovant Sciences Free Cash Flow is fairly stable at the moment as compared to the past year. Myovant Sciences reported Free Cash Flow of 368.86 Million in 2020. Invested Capital is likely to climb to about 149.9 M in 2021, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (261 M) in 2021.

Search Financial Statements 

 
Refresh
Check Myovant Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Myovant main balance sheet or income statement drivers, such as Cost of Revenue of 269.3 K, Gross Profit of 52.8 M or Interest Expense of 10.4 M, as well as many exotic indicators such as Asset Turnover of 0.12, Current Ratio of 2.92 or Free Cash Flow per Share of 4.42. Myovant financial statements analysis is a perfect complement when working with Myovant Sciences Valuation or Volatility modules. It can also supplement various Myovant Sciences Technical models. Additionally, see the analysis of Myovant Sciences Correlation against competitors.

Myovant Sciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets782.3 M725 M266.9 M
Increasing
Slightly volatile
Cash and Equivalents727.7 M674.5 M250.8 M
Increasing
Slightly volatile
Investments9.4 M10.4 M4.1 M
Increasing
Slightly volatile
Investments Current9.4 M10.4 M4.1 M
Increasing
Slightly volatile
Deferred Revenue417.8 M497.9 M109.6 M
Increasing
Slightly volatile
Property Plant and Equipment Net10.4 M13 M3.9 M
Increasing
Slightly volatile
Inventory2.3 M2.3 M2.6 M
Decreasing
Slightly volatile
Tax Assets671.7 K602.6 K459.4 K
Increasing
Slightly volatile
Trade and Non Trade Receivables3.2 M3.2 M3.5 M
Decreasing
Slightly volatile
Trade and Non Trade Payables16.6 M18.4 M9.6 M
Increasing
Slightly volatile
Total Liabilities1.2 B1.1 B236.4 M
Increasing
Slightly volatile
Shareholders Equity(363.3 M)(354 M)32 M
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income(17.7 M)(17.3 M)(2.9 M)
Decreasing
Slightly volatile
Current Assets760.3 M704.6 M260.3 M
Increasing
Slightly volatile
Assets Non Current16.5 M20.4 M6.1 M
Increasing
Slightly volatile
Current Liabilities303.6 M281.3 M75.7 M
Increasing
Slightly volatile
Liabilities Non Current860.6 M797.7 M160.7 M
Increasing
Slightly volatile
Total Debt398.9 M369.7 M111.9 M
Increasing
Slightly volatile
Debt Current2.3 M1.8 M5.1 M
Decreasing
Slightly volatile
Debt Non Current396.9 M367.9 M111 M
Increasing
Slightly volatile
Shareholders Equity USD(363.3 M)(354 M)32 M
Decreasing
Slightly volatile
Cash and Equivalents USD727.7 M674.5 M250.8 M
Increasing
Slightly volatile
Total Debt USD398.9 M369.7 M111.9 M
Increasing
Slightly volatile

Myovant Sciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues53.1 M53.4 M58.3 M
Decreasing
Slightly volatile
Cost of Revenue269.3 K270.9 K295.9 K
Decreasing
Slightly volatile
Selling General and Administrative Expense195.7 M181.4 M51 M
Increasing
Slightly volatile
Research and Development Expense154.4 M136.7 M94 M
Increasing
Slightly volatile
Operating Expenses289.6 M318.1 M140 M
Increasing
Slightly volatile
Interest Expense10.4 M10.4 M4.9 M
Increasing
Slightly volatile
Income Tax Expense375.1 K336 K136.9 K
Increasing
Slightly volatile
Weighted Average Shares88.1 M90 M61.2 M
Increasing
Slightly volatile
Weighted Average Shares Diluted88.1 M90 M61.2 M
Increasing
Slightly volatile
Revenues USD53.1 M53.4 M58.3 M
Decreasing
Slightly volatile
Gross Profit52.8 M53.1 M58 M
Decreasing
Slightly volatile

Myovant Sciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing229.9 M238 M194.5 M
Increasing
Very volatile
Issuance Repayment of Debt Securities 195 M245 M79.8 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares6.9 M6.7 M119.5 M
Decreasing
Slightly volatile
Net Cash Flow from Operations399.9 M370.6 M6.7 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents646.8 M599.5 M200.8 M
Increasing
Stable
Share Based Compensation43.6 M53.7 M19.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion2.7 M2.5 M668.9 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity1.091.0640.524
Increasing
Slightly volatile
Return on Invested Capital(1.49)(1.381)1.5565
Decreasing
Slightly volatile
Gross Margin0.890.90.9787
Decreasing
Slightly volatile
Asset Turnover0.120.120.1326
Decreasing
Slightly volatile
Sales per Share0.590.590.6475
Decreasing
Slightly volatile
Price to Sales Ratio27.9528.1130.7031
Decreasing
Slightly volatile
Price to Book Value(5.42)(5.279)36.427
Increasing
Stable
Debt to Equity Ratio(3.13)(3.048)2.8075
Increasing
Stable
Current Ratio2.922.5056.8466
Decreasing
Slightly volatile
Free Cash Flow per Share4.424.097(0.1792)
Increasing
Stable
Book Value per Share(4.03)(3.931)1.2677
Decreasing
Slightly volatile
Tangible Assets Book Value per Share8.698.0534.0778
Increasing
Slightly volatile

Myovant Sciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization1.7 B1.9 BB
Increasing
Slightly volatile
Enterprise Value1.4 B1.5 B835.7 M
Increasing
Slightly volatile
Invested Capital149.9 M138.9 M26.9 M
Increasing
Slightly volatile
Average Equity(246.1 M)(239.8 M)14.8 M
Decreasing
Slightly volatile
Average Assets349.5 M440.4 M161.6 M
Increasing
Slightly volatile
Invested Capital Average191 M177 M37.2 M
Increasing
Slightly volatile
Tangible Asset Value782.3 M725 M266.9 M
Increasing
Slightly volatile
Free Cash Flow398 M368.9 M5.6 M
Increasing
Slightly volatile
Working Capital456.7 M423.3 M184.6 M
Increasing
Slightly volatile

Myovant Fundamental Market Drivers

Short Percent Of Float7.37%
Forward Price Earnings-15.60
Shares Short Prior Month3.68M
Average Daily Volume Last 10 Day719.07k
Average Daily Volume In Three Month721.83k
Date Short Interest28th of May 2021
Fifty Day Average21.57
Two Hundred Day Average21.67

Myovant Upcoming Events

Upcoming Quarterly Report28th of July 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of May 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

About Myovant Sciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Myovant Sciences income statement, its balance sheet, and the statement of cash flows. Myovant Sciences investors use historical funamental indicators, such as Myovant Sciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Myovant Sciences investors may use each financial statement separately, they are all related. The changes in Myovant Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Myovant Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Myovant Sciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Myovant Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Deferred Revenue497.9 M417.8 M
Cost of Revenue270.9 K269.3 K
Revenues53.4 M53.1 M
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Myovant Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Myovant Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Myovant Sciences Correlation against competitors. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.